South Korean biotechnology firm GC Cell began transferring its cancer immunotherapy technology to Indonesia’s PT Bifarma, pushing to expand its presence in Southeast Asia’s largest pharmaceutical market.
The six-month technology transfer, which started in November, follows a September licensing agreement for GC Cell’s Immuncell-LC treatment with Bifarma, a cell therapy subsidiary of KALBE Group. The process includes comprehensive training on production and quality control protocols at GC Cell’s headquarters.
The move represents the first commercial introduction of anti-cancer immune cell therapy in Indonesia. Bifarma plans to begin local production and distribution immediately after completing the technology transfer process.
Immuncell-LC is a personalized treatment that utilizes a patient’s own immune cells to combat cancer. The therapy is part of GC Cell’s broader portfolio of cell-based treatments in regenerative medicine.
This marks GC Cell’s first international technology transfer under its licensing program, suggesting a shift in strategy toward global expansion. The collaboration with KALBE Group, Southeast Asia’s largest pharmaceutical company, could provide GC Cell with access to a significant market for its cancer therapies.
